865 related articles for article (PubMed ID: 25936321)
21. Plasma lipoprotein(a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients.
Baldassarre D; Tremoli E; Franceschini G; Michelagnoli S; Sirtori CR
Stroke; 1996 Jun; 27(6):1044-9. PubMed ID: 8650712
[TBL] [Abstract][Full Text] [Related]
22. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.
Tselmin S; Müller G; Schatz U; Julius U; Bornstein SR; Hohenstein B
Atheroscler Suppl; 2017 Nov; 30():209-216. PubMed ID: 29096840
[TBL] [Abstract][Full Text] [Related]
23. Actual situation of lipoprotein apheresis in Saxony in 2013.
Emmrich U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
[TBL] [Abstract][Full Text] [Related]
24. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
[TBL] [Abstract][Full Text] [Related]
25. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
Schampera S; Fischer S; Weiss N; Julius U
Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
[TBL] [Abstract][Full Text] [Related]
26. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
Schatz U; Tselmin S; Müller G; Julius U; Hohenstein B; Fischer S; Bornstein SR
Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
[TBL] [Abstract][Full Text] [Related]
27. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
[TBL] [Abstract][Full Text] [Related]
28. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia.
van Wissen S; Smilde TJ; Trip MD; de Boo T; Kastelein JJ; Stalenhoef AF
Heart; 2003 Aug; 89(8):893-6. PubMed ID: 12860867
[TBL] [Abstract][Full Text] [Related]
29. Changing characteristics of statin-related cIMT trials from 1988 to 2006.
Davidson MH; Tomassini JE; Jensen E; Neff D; Polis AB; Tershakovec AM
Atherosclerosis; 2016 Mar; 246():121-9. PubMed ID: 26773471
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
Puri R; Ballantyne CM; Hoogeveen RC; Shao M; Barter P; Libby P; Chapman MJ; Erbel R; Arsenault BJ; Raichlen JS; Nissen SE; Nicholls SJ
Atherosclerosis; 2017 Aug; 263():137-144. PubMed ID: 28641153
[TBL] [Abstract][Full Text] [Related]
31. Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical data.
Pokrovsky SN; Sussekov AV; Afanasieva OI; Adamova IY; Lyakishev AA; Kukharchuk VV
Chem Phys Lipids; 1994 Jan; 67-68():323-30. PubMed ID: 8187230
[TBL] [Abstract][Full Text] [Related]
32. Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.
Poller WC; Berger A; Dreger H; Morgera S; Enke-Melzer K
Atheroscler Suppl; 2017 Nov; 30():174-179. PubMed ID: 29096834
[TBL] [Abstract][Full Text] [Related]
33. Relationship between lipoprotein(a) concentrations and intima-media thickness: a healthy population study.
Calmarza P; Trejo JM; Lapresta C; Lopez P
Eur J Prev Cardiol; 2012 Dec; 19(6):1290-5. PubMed ID: 21914687
[TBL] [Abstract][Full Text] [Related]
34. Extended-release niacin or ezetimibe and carotid intima-media thickness.
Taylor AJ; Villines TC; Stanek EJ; Devine PJ; Griffen L; Miller M; Weissman NJ; Turco M
N Engl J Med; 2009 Nov; 361(22):2113-22. PubMed ID: 19915217
[TBL] [Abstract][Full Text] [Related]
35. Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study.
Stefanutti C; D'Alessandri G; Russi G; De Silvestro G; Zenti MG; Marson P; Belotherkovsky D; Vivenzio A; Di Giacomo S
Atheroscler Suppl; 2009 Dec; 10(5):89-94. PubMed ID: 20129383
[TBL] [Abstract][Full Text] [Related]
36. Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a).
Poller WC; Dreger H; Morgera S; Berger A; Flessenkämper I; Enke-Melzer K
Atheroscler Suppl; 2015 May; 18():187-93. PubMed ID: 25936325
[TBL] [Abstract][Full Text] [Related]
37. Effects of lipoprotein apheresis on PCSK9 levels.
Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
[TBL] [Abstract][Full Text] [Related]
38. Lipoprotein(a) apheresis.
Pokrovsky SN; Afanasieva OI; Ezhov MV
Curr Opin Lipidol; 2016 Aug; 27(4):351-8. PubMed ID: 27213629
[TBL] [Abstract][Full Text] [Related]
39. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Davidson MH; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Mazzone T; Carlson DM; Williams LA; Kelly MT; Camp HS; Lele A; Stolzenbach JC
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1298-306. PubMed ID: 24743431
[TBL] [Abstract][Full Text] [Related]
40. [Lipoprotein(a) is associated to atherosclerosis in primary hypercholesterolemia].
Bea AM; Mateo-Gallego R; Jarauta E; Villa-Pobo R; Calmarza P; Lamiquiz-Moneo I; Cenarro A; Civeira F
Clin Investig Arterioscler; 2014; 26(4):176-83. PubMed ID: 24576773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
